centered image

centered image

Upadacitinib Shows Benefit In Psoriatic Arthritis, Higher Dose Bests Adalimumab

Discussion in 'General Discussion' started by The Good Doctor, Apr 1, 2021.

  1. The Good Doctor

    The Good Doctor Golden Member

    Aug 12, 2020
    Likes Received:
    Trophy Points:

    In patients with active psoriatic arthritis, daily oral upadacitinib produces significantly more improvement than placebo, but only recipients of the 30 mg dose experienced a significantly better outcome than with standard treatment with adalimumab, according to results from the SELECT-PsA 1 study.

    Success was measured by a decrease of at least 20% in the number of tender and swollen joints and an improvement of at least 20% on three of five domains in an American College of Rheumatology Scale after 12 weeks of therapy.

    By that metric the treatment success rate was 36.2% with placebo, 65.0% with adalimumab, 70.6% with 15 mg of upadacitinib daily and 78.5% with 30 mg daily. Only the 30 mg dose was superior to adalimumab.

    When it came to improvements of at least 70%, the rates at 12 weeks were 2.4%, 13.8%, 15.6% and 25.3%, respectively.


    The adverse-event rates, assessed through week 24, were similar in the four groups, but hepatic disorders were seen in 9.1% who got lower-dose upadacitinib, 12.3% who received the higher dose, and 15.6% on adalimumab.

    "The incidence of serious infections was 1.2% with the 15-mg dose of upadacitinib, 2.6% with the 30-mg dose of upadacitinib, 0.9% with placebo, and 0.7% with adalimumab," Dr. Iain McInnes of the University of Glasgow and colleagues report in the New England Journal of Medicine.

    AbbVie paid for the phase-3 trial, designed it, and helped collect, analyze and interpret the data. The company reported topline results for the trial on February 5, 2020. The drug is sold under the brand name Rinvoq as a treatment for rheumatoid arthritis.

    The study looked at 1,704 volunteers who were not well controlled by or had too many side effects from non-biologic disease-modifying arthritis drugs. It was done at 281 sites in 45 countries.

    The high-dose treatment would cost more than $10,000 a month and the low-dose regimen would be half that, according to prices on The adalimumab therapy used in the study costs $6,000 a month, based on data from the website.

    —Reuters Staff


    Add Reply

Share This Page